Application and Selection Process
For further information on the application and selection process, please refer to the Round 2 Funding Guidelines.
For any queries about your application, email: venturer@biointelect.com.
EOIs for Round 2 are now closed
Application and Selection Process
The application and selection process includes expert review and recommendation by an independent Investment Review Committee (IRC), composed of internationally and nationally recognised experts with deep expertise spanning vaccine and therapeutic product development, infectious diseases, pre-clinical and clinical development, regulatory affairs, and manufacturing and process development.
IRC recommendations are reviewed and endorsed by the Biointelect Venturer Steering Committee. The Steering Committee is an independent, nationally representative advisory group that provides expert advice on the operations of the incubator.
The Consumer Advisory Group (CAG), consisting of consumers from diverse backgrounds, provides a complementary perspective within the incubator’s governance framework by ensuring that consumer and community views help inform decision-making.
All IRC and Steering Committee recommendations and endorsements are reviewed for approval by the Biointelect Board, ensuring a rigorous, transparent and fair decision-making process.
Applications are evaluated through a structured, multi-stage process:
Phase 1: Expression of Interest (EOI)
Applicants must submit a non-confidential EOI addressing the published selection criteria. EOIs will be screened for eligibility by the Biointelect Venturer team.
Phase 2: Targeted Due Diligence
Eligible EOIs will undergo a targeted due diligence review by the Biointelect Venturer team, with EOIs and associated due diligence outputs then assessed by the IRC.
Shortlisted EOIs, confirmed through a post-evaluation IRC calibration process, are submitted for endorsement by the Biointelect Venturer Steering Committee and approval by the Biointelect Board, before being invited to progress to Phase 3 and submit a full application.
Phase 3: Full Application
Preparation and submission of a full application that expands on the EOI, and addresses any feedback received during the EOI process, to provide a more comprehensive outline of the technology and proposed project. The IRC, with input from the CAG and technical experts where required, assess full applications against defined selection criteria and ranked accordingly.
Shortlisted applicants will be invited to participate in an interview with a panel comprising of representatives of the Biointelect Venturer team, the IRC and Steering Committee, where applicants will have an opportunity to respond to specific questions that may have arose during the assessment process.
Phase 4: Final Selection and Award
Outputs from the applicant interviews inform the final recommendations for funding, which are submitted for endorsement to the Steering Committee and subsequently reviewed and approved by the Biointelect Board prior to award and contracting.
